Crescendo Bioscience, Inc. (NASDAQ:MYGN)

CAPS Rating: 3 out of 5

Myriad Genetics is focused on developing and marketing novel molecular diagnostic products.

Recs

0
Player Avatar SharpNJ104 (32.18) Submitted: 4/16/2012 6:02:57 PM : Outperform Start Price: $24.07 MYGN Score: +22.53

Great product without the downside risks of drugs. Increasing contracts with other drug companies for use of their genetic tests for the drug co's drug trials. The future of medicine is personalized based on each inidividual.

Featured Broker Partners


Advertisement